AT-Bio is dedicated to the development of Western medicines for Chinese and global markets. Our first objective is to license-in and develop small molecule Western medicines, according to international regulatory and intellectual property standards.
AT-Bio has the scientific capabilities and financial resources necessary to take candidates all the way from early discovery stage into successful clinical trials.
Our therapeutic areas of interest are:
AT-Bio Pty Ltd is an officially approved foreign joint venture company established by the Tianjin Institute of Pharmaceutical Research (TIPR) and Atholl Biotechnology Management.
Jim Murray, CEO
Tel (Australia) : +613 9574 7551
Tel (China) : 022 23006950
Fax : +613 9574 7457
Enquiries : jmurray@atbio.com.au
Bio 21 Institute
30 Flemington Road
University of Melbourne
Parkville Australia 3010
308 An Shan Xi Dao
Tianjin China 300193